The acquisition is a small bolt-on that should modestly boost revenue and margins. No debt or equity issuance was used. Monitor the Q3 2026 10-Q (due by Oct 15) for integration details and margin impact. The deal does not change UTMD's core strategy but provides a stable, accretive revenue stream.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 31 $71.13entry
- T+1 · 3mo ago +0.89%α +1.57% · $71.76
- T+5 · 2mo ago −2.77%α −2.63% · $69.16
- T+20 · 7w ago +5.37%α +5.56% · $74.95
- T+54 · todayOpen
- T+60 · in 7d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UTMD's UK subsidiary Femcare Ltd acquired all shares of Orion Medical Supplies Ltd for 3.6 million in cash. Orion is a niche harm-reduction device assembler/distributor; the deal is expected to add ~$6M to UTMD's annual sales and be accretive by leveraging existing Femcare infrastructure. The acquisition is small relative to UTMD's $232M market cap but uses cash reserves with no dilution.
Key Facts
- Purchase price of 3.6 million paid from cash reserves
- Expected to add about $6 million to UTMD's consolidated annual sales
- Orion is a UK-based assembler/distributor of harm reduction medical devices
- Acquisition is not synergistic from a medical use perspective but is accretive via overhead leverage
- Orion's operations will move into Femcare's existing Romsey facilities after a transition period
Financial Impact
Adds ~$6M to annual revenue (approx. 10-12% of current sales) for a cash purchase price of 3.6M; accretive due to overhead dilution
Risk Factors
- Integration risk as Orion's harm reduction products are not synergistic with UTMD's existing device portfolio
- Potential distraction from core business during facility move and transition
- Limited growth upside given the niche market and retiring founders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001096906-26-001326 |
| Document: utmd_ex99z1.htm | 0001096906-26-001326 |
| Document: 0001096906-26-001326-index-headers.html | 0001096906-26-001326 |
| Document: 0001096906-26-001326-index.html | 0001096906-26-001326 |
| Document: 0001096906-26-001326.txt | 0001096906-26-001326 |
Track record
11 reports on UTMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $70.02 Now $72.36 +3.34% settles Dec 2
- Oct 29, 202618d ago Insider Buy Neutral 3/10 Entry $68.08 Now $72.36 +6.29% settles Nov 30
- Oct 29, 202618d ago SC TO-I/A Neutral 4/10 Entry $66.80 Now $72.36 +8.32% settles Nov 27
- Oct 22, 202625d ago 8-K Mixed 5/10 Entry $75.06 Now $72.36 −3.60% settles Nov 19
- Oct 5, 20266w ago SC TO-I/A Neutral 3/10 Entry $73.31 to $68.08 Now $72.36 −1.30% ▼ −7.14% −4.67% vs SPY
- Sep 25, 20267w ago SC TO-C Neutral 2/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
- Sep 24, 20267w ago SC TO-C Mixed 6/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
- Sep 23, 20267w ago SC TO-I Mixed 5/10 Entry $74.75 to $75.06 Now $72.36 −3.20% ▲ +0.41% +0.83% vs SPY
- Aug 31, 202611w ago 8-K Bullish 5/10 Viewing Entry $71.13 to $74.95 Now $72.36 +1.73% ▲ +5.37% +5.56% vs SPY
- Jul 23, 202616w ago 8-K Bearish 7/10 Entry $64.18 to $71.42 Now $72.36 −12.75% ▼ −11.28% −7.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers